Patents by Inventor Qingfu Zeng

Qingfu Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chain, continuous and no-waste method for degumming and fiber-separating the ramie
    Patent number: 9206544
    Abstract: The present invention relates to a chain, continuous and no-waste method for degumming and fiber-separating the ramie, including anaerobic circle step, in which the raw fibers after the waste alkali bath step are immersed in the anaerobic water pool; aerobic circle step, in which the raw fibers after the anaerobic circle step are immersed in the aerobic water pool; alkali-hydrogen peroxide one bath scouring-bleaching step, in which the raw fibers after the aerobic circle step are immersed in a combined solution of NaOH and H2O2; and the treatment by a fiber-separating and washing device followed by the immersion in the cellulase solution. In the present invention, the ramie degumming process and the degumming wastewater treatment are performed integratively, and the degumming wastewater is completely recycled after treatment.
    Type: Grant
    Filed: August 22, 2014
    Date of Patent: December 8, 2015
    Assignee: WUHAN TEXTILE UNIVERSITY
    Inventors: Qingfu Zeng, Gongbing Su, Xuejun Long, Fei Pan, Haiying Chen, Qian Wang, Honggao Chen, Yongming Cui, Ping Zhang, Jin Li, Jun Wang
  • CHAIN, CONTINUOUS AND NO-WASTE METHOD FOR DEGUMMING AND FIBER-SEPARATING THE RAMIE
    Publication number: 20150240414
    Abstract: The present invention relates to a chain, continuous and no-waste method for degumming and fiber-separating the ramie, including anaerobic circle step, in which the raw fibers after the waste alkali bath step are immersed in the anaerobic water pool; aerobic circle step, in which the raw fibers after the anaerobic circle step are immersed in the aerobic water pool; alkali-hydrogen peroxide one bath scouring-bleaching step, in which the raw fibers after the aerobic circle step are immersed in a combined solution of NaOH and H2O2; and the treatment by a fiber-separating and washing device followed by the immersion in the cellulase solution. In the present invention, the ramie degumming process and the degumming wastewater treatment are performed integratively, and the degumming wastewater is completely recycled after treatment.
    Type: Application
    Filed: August 22, 2014
    Publication date: August 27, 2015
    Inventors: Qingfu Zeng, Gongbing Su, Xuejun Long, Fei Pan, Haiying Chen, Qian Wang, Honggao Chen, Yongming Cui, Ping Zhang, Jin Li, Jun Wang
  • Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-alpha
    Patent number: 8466160
    Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.
    Type: Grant
    Filed: December 30, 2010
    Date of Patent: June 18, 2013
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Roberto Polakiewicz, Ailan Guo, Katherine Eleanor Crosby, Qingfu Zeng, Kimberly A Lee
  • Identification of Non-Small Cell Lung Carcinoma (NSCLC) Tumors Expressing PDGFR-ALPHA
    Publication number: 20110195447
    Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.
    Type: Application
    Filed: December 30, 2010
    Publication date: August 11, 2011
    Applicant: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Roberto Polakiewicz, Ailan Guo, Katherine Crosby, Qingfu Zeng, Kimberly Lee
  • Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-?
    Patent number: 7932044
    Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.
    Type: Grant
    Filed: July 1, 2005
    Date of Patent: April 26, 2011
    Assignee: Cell Signaling Technology, Inc.
    Inventors: Klarisa Rikova, Roberto Polakiewicz, Ailan Guo, Katherine Crosby, Qingfu Zeng, Kimberly Lee
  • Identification of non-small cell lung carcinoma (NSCLC) tumors expressing PDGFR-alpha
    Publication number: 20070148711
    Abstract: The invention discloses a previously unidentified subset of mammalian non-small cell lung carcinomas (NSCLC) in which platelet-derived growth factor receptor alpha (PDGFR?) is expressed and is driving the disease, and provides methods for identifying a mammalian NSCLC tumor that belongs to a subset of NSCLC tumors in which PDGFR? is expressed, and for identifying a NSCLC tumor that is likely to respond to a PDGFR?-inhibiting therapeutic. The invention also provides methods for inhibiting the progression of a mammalian NSCLC tumor in which PDGFR? is expressed, and for determining whether a compound inhibits the progression of a PDGFR?-expressing mammalian NSCLC tumor.
    Type: Application
    Filed: July 1, 2005
    Publication date: June 28, 2007
    Inventors: Klarisa Rikova, Roberto Polakiewicz, Ailan Guo, Katherine Crosby, Qingfu Zeng, Kimberly Lee